Summary
Industry
Insights
Pear Bio, based in London, is disrupting healthcare with its cancer treatment predictor software. Operating on a B2B model, Pear Bio aims to enhance oncologists' decision-making through advanced predictive analytics. Unlike traditional methods reliant on clinical trials and historical data, Pear Bio’s software directly predicts effective cancer treatments, potentially reducing less effective treatments and patient suffering. Supported by investors like Hoxton Ventures and Octopus Ventures, Pear Bio is poised to innovate in the biotech and health tech sectors.